Key Details
Price
$291.50Last Dividend
$0.89Annual ROE
15.71%Beta
0.49Events Calendar
Next earnings date:
Feb 11, 2025Recent quarterly earnings:
Oct 30, 2024Recent annual earnings:
Jan 25, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Dec 31, 2024Next split:
N/ARecent split:
Aug 01, 1991Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Humana (HUM) saw an increase in its share price during the last trading session, with trading volume higher than usual. However, the recent changes in earnings estimates for the stock do not indicate that this upward trend will continue in the future.
Talicia is now included in Humana's Part D Plan, allowing over eight million more Medicare patients to access it for H. pylori treatment without needing prior approval or steps. The latest guidelines from the American College of Gastroenterology (ACG) recommend Talicia as a top choice for H. pylori therapy.
Humana (HUM) has a strong track record of surprising with its earnings and currently has the right mix of factors that suggest it may exceed expectations in its upcoming quarterly report.
The Zacks Earnings ESP is an excellent tool for identifying possible earnings surprises. Investors should consider using it right now.
HUM is in a strong position for growth due to better premiums, successful contracts, acquisitions, partnerships, and increasing cash reserves.
At Zacks, we concentrate on the reliable Zacks Rank system, which highlights earnings estimates and changes in those estimates to identify excellent stocks. At the same time, we keep an eye on the most recent trends in value, growth, and momentum to support our top selections.
This Industry Outlook article has pointed out UnitedHealth, Humana, and Centene.
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) will announce its financial results for the fourth quarter of 2024 on Tuesday, February 11, 2025, at 6:30 a.m. Eastern time, along with management comments in PDF format. The company will also hold a live Q&A session at 9:00 a.m. Eastern time that same day to go over the quarterly results and provide earnings guidance for 2025. To join the call, please register in advance using the provided link.
The healthcare sector, especially Pharmacy Benefit Managers (PBMs), is under bipartisan examination, causing a drop in stock prices for Humana and Cigna, which could be a chance for investors. President-elect Donald Trump's views on PBMs and new bipartisan laws suggest possible regulatory changes, leading to uncertainty for companies linked to PBMs. Even with recent financial challenges, Cigna and Humana are experiencing solid revenue growth, although short-term profits are affected by investment losses and increasing benefit costs.
Humana's stock has dropped by 18%, while the S&P 500 has gained 13.5%, mainly due to temporary problems with Medicare Advantage. Even with these short-term cost difficulties, Medicare Advantage is still expected to benefit the company in the long run, and the value of CenterWell coordinated care is not yet reflected in Humana's plans. I still recommend buying the stock, with a target price of $370, which suggests a potential increase of 28%.
FAQ
- What is the primary business of Humana?
- What is the ticker symbol for Humana?
- Does Humana pay dividends?
- What sector is Humana in?
- What industry is Humana in?
- What country is Humana based in?
- When did Humana go public?
- Is Humana in the S&P 500?
- Is Humana in the NASDAQ 100?
- Is Humana in the Dow Jones?
- When was Humana's last earnings report?
- When does Humana report earnings?
- Should I buy Humana stock now?